Diasorin S.P.A. operates within the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Diasorin S.P.A. with three other
pharmaceutical manufacturers in Europe:
Swedish Orphan Biovitrum AB (publ)
sales of 6.51 billion Swedish Kronor [US$794.73 million]
Siegfried Holding AG
(750.47 million Swiss Francs [US$788.31 million]
of which 77%
was Drug Substances), and
based in Spain
(639.38 million Euro [US$785.48 million]
of which 71%
was Own Network (Spain)).
During the year ended December of 2017, sales at
Diasorin S.P.A. were 637.50 million Euro (US$783.17 million).
increase of 12.0%
versus 2016, when the company's sales were 569.31 million Euro.
This was the fifth consecutive year of sales increases at Diasorin S.P.A.
(and since 2012, sales have increased a total of 47%).